Com­ing out of Chap­ter 11, Aege­ri­on jumps in­to wel­come arms of Irish phar­ma with big plans, fresh $60M for its drugs

Am­ryt Phar­ma didn’t make much of a splash in May when it struck a deal to ac­quire Nov­e­l­ion’s Aege­ri­on sub­sidiary, ab­sorb­ing two com­mer­cial drugs and a US in­fra­struc­ture in an all-stock deal. But now that the trans­ac­tion has been wrapped, the Dublin-based com­pa­ny is ready to bring some re­newed at­ten­tion to it — as well as a fresh $60 mil­lion raise.

The fi­nanc­ing al­lows Am­ryt to con­tin­ue rolling out Myalep­ta in Eu­rope while al­so tak­ing over glob­al re­spon­si­bil­i­ties for the drug (known as Myalept in the US), which treats lipody­s­tro­phy, and a ho­mozy­gous fa­mil­ial hy­per­c­ho­les­terolemia ther­a­py called Jux­tapid/Lo­jux­ta. Am­ryt has been mar­ket­ing Lo­jux­ta in Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER